Innovative Medicine
-
New Idylla™ Ebola Virus Triage Test Granted Emergency Use Authorization by U.S. FDA
Co-Developed by Janssen Diagnostics, test will help prevent future outbreaks of Ebola -
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis
SIMPONI Recommended for Sixth Indication in Europe and First in Pediatric Population -
U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes
In a Phase 3 study of patients not previously treated with any diabetes medication, combination therapy with canagliflozin and metformin lowered blood sugar more than either medicine alone -
New Phase 3 Study Findings Show STELARA® Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn’s Disease
Approximately 50 Percent of STELARA®-treated Patients Achieved Clinical Remission According to Pivotal Phase 3 IM-UNITI Study Results Presented for the First Time at Digestive Disease Week® 2016 -
-
-
Janssen Submits Application to U.S. FDA Seeking Approval of a Mebendazole Chewable Tablet for the Treatment of Soil-Transmitted Helminthiasis
Chewable formulation of mebendazole will address an unmet need in treating intestinal worms in young children -
Janssen’s IMBRUVICA® (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
Recommendation based on RESONATE™-2 trial which showed IMBRUVICA significantly improved progression-free survival and prolonged overall survival versus chlorambucil -
Global Public-Private Partnership Announces Publication of Positive Phase 1 Data for Ebola Vaccine Regimen in JAMA
First published clinical data show prime-boost Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization. An Ebola vaccine is still urgently needed to address the problem of Ebola persistence in affected countries and to prevent future outbreaks. Partners involved in the clinical program for the Ebola vaccine regimen include the Janssen Pharmaceutical Companies of Johnson & Johnson, the London School of Hygiene & Tropical Medicine, the University of Oxford, Inserm, Bavarian Nordic and Europe’s Innovative Medicines Initiative.